Rapport Therapeutics

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.